GT199900137A - Polimorfo de monohidrato de zopolrestat. - Google Patents

Polimorfo de monohidrato de zopolrestat.

Info

Publication number
GT199900137A
GT199900137A GT199900137A GT199900137A GT199900137A GT 199900137 A GT199900137 A GT 199900137A GT 199900137 A GT199900137 A GT 199900137A GT 199900137 A GT199900137 A GT 199900137A GT 199900137 A GT199900137 A GT 199900137A
Authority
GT
Guatemala
Prior art keywords
monohidrate
zopolrestat
polymorph
àcid
procedure
Prior art date
Application number
GT199900137A
Other languages
English (en)
Inventor
Jhon Francis Lambert
Timothy Norris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900137A publication Critical patent/GT199900137A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

ESTA INVENCIÒN SE REFIERE A MONOHIDRATO DE ZOPOLRESTAT Y A SUS POLIMORFOS, PROCEDIMIENTO PARA PREPARARLO COMO MONOHIDRATO, ANHIDRO, O POLIMORFO. ASÌ TAMBIEN A SU PROCEDIMIENTO DE USO EN COMPOSICIONES PARA TRATAR COMPLICACIONES DIABÈTICAS (CATARATAS, RETINOPATÌA O NEUROPATÌA DIABÈTICAS), REDUCCIÒN DE LOS NIVELES DE LÌPIDOS EN SANGRE O EL NIVEL DE ÀCIDO ÙRICO EN SANGRE. EL ZOPOLRESTAT, TAMBIEN ES CONOCIDO COMO: ÀCIDO 3,4DIHIDRO4OXO 3((5TRIFLUOROMETIL)2BENZOTIAZOLIL) METIL1FTALAZINOACÈTICO, REPRESENTADA ABAJO CÒMO
GT199900137A 1998-08-21 1999-08-19 Polimorfo de monohidrato de zopolrestat. GT199900137A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9747498P 1998-08-21 1998-08-21

Publications (1)

Publication Number Publication Date
GT199900137A true GT199900137A (es) 2001-02-09

Family

ID=22263562

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900137A GT199900137A (es) 1998-08-21 1999-08-19 Polimorfo de monohidrato de zopolrestat.

Country Status (31)

Country Link
US (1) US6159976A (es)
EP (1) EP0982306A3 (es)
JP (1) JP2000072769A (es)
KR (1) KR20000017411A (es)
CN (1) CN1245804A (es)
AP (1) AP9901662A0 (es)
AU (1) AU4453299A (es)
BG (1) BG103674A (es)
BR (1) BR9903873A (es)
CA (1) CA2280590A1 (es)
EA (1) EA199900675A3 (es)
EE (1) EE9900385A (es)
GT (1) GT199900137A (es)
HR (1) HRP990259A2 (es)
HU (1) HUP9902783A3 (es)
ID (1) ID23307A (es)
IL (1) IL131419A0 (es)
IS (1) IS5155A (es)
MA (1) MA26678A1 (es)
NO (1) NO994027L (es)
NZ (1) NZ337363A (es)
OA (1) OA11150A (es)
PA (1) PA8480601A1 (es)
PE (1) PE20000993A1 (es)
PL (1) PL335016A1 (es)
SG (1) SG83147A1 (es)
TN (1) TNSN99159A1 (es)
TR (1) TR199901996A2 (es)
UY (1) UY25668A1 (es)
YU (1) YU39899A (es)
ZA (1) ZA995297B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105732640B (zh) 2010-07-16 2019-01-08 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂及其用途
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
WO2014126885A1 (en) * 2013-02-13 2014-08-21 Mylari Banavara L Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
MX2018016122A (es) 2016-06-21 2019-08-01 Univ Columbia Inhibidores de aldosa reductasa y metodos de uso.
CN111065392A (zh) 2017-07-28 2020-04-24 应用治疗公司 用于治疗半乳糖血症的组合物和方法
CA3132136A1 (en) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
EP4125909A1 (en) 2020-03-31 2023-02-08 Applied Therapeutics Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
CA3176768A1 (en) 2020-05-01 2021-11-04 Shoshana SHENDELMAN Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
WO1992003432A1 (en) * 1990-08-28 1992-03-05 Pfizer Inc. 3-(5-trifluoromethylbenzothiazol-2-ylmethyl)-4-oxo-3h-phythalazin-1-ylacetic acid monohydrate
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
IL120264A0 (en) * 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia

Also Published As

Publication number Publication date
PL335016A1 (en) 2000-02-28
OA11150A (en) 2003-04-16
TNSN99159A1 (fr) 2005-11-10
NZ337363A (en) 2001-01-26
EP0982306A2 (en) 2000-03-01
EP0982306A3 (en) 2000-07-05
YU39899A (sh) 2002-12-10
NO994027L (no) 2000-02-22
EE9900385A (et) 2000-04-17
AP9901662A0 (en) 1999-09-30
BR9903873A (pt) 2000-09-19
CA2280590A1 (en) 2000-02-21
IL131419A0 (en) 2001-01-28
ZA995297B (en) 2001-02-19
EA199900675A2 (ru) 2000-02-28
EA199900675A3 (ru) 2000-06-26
US6159976A (en) 2000-12-12
NO994027D0 (no) 1999-08-20
PA8480601A1 (es) 2000-09-29
TR199901996A2 (xx) 2000-03-21
ID23307A (id) 2000-04-05
IS5155A (is) 2000-02-22
PE20000993A1 (es) 2000-10-04
HUP9902783A3 (en) 2001-01-29
JP2000072769A (ja) 2000-03-07
UY25668A1 (es) 2001-08-27
HRP990259A2 (en) 2000-06-30
CN1245804A (zh) 2000-03-01
AU4453299A (en) 2000-03-09
SG83147A1 (en) 2001-09-18
HUP9902783A2 (hu) 2000-12-28
HU9902783D0 (en) 1999-10-28
MA26678A1 (fr) 2004-12-20
KR20000017411A (ko) 2000-03-25
BG103674A (en) 2000-03-31

Similar Documents

Publication Publication Date Title
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
GT199900217A (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
BR0114630A (pt) Secretagogos de hormÈnio do crescimento
GT200000069A (es) Derivados heterociclicos utiles como agentes anticancerosos.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
HN1998000157A (es) Agonistas de prostaglandinas
ES2162942T3 (es) Nuevos derivados de acidos carboxilicos, su obtencion y empleo.
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
BR0111358A (pt) Compostos de tioacetamida e seu uso
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ECSP941135A (es) Antagonistas triciclicos de vasopresina de benzacepina
PA8543201A1 (es) DERIVADOS DE DIHIDRO-BENZO [B] [1,4]-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGluR2
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
MA27501A1 (fr) Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3
BRPI0414858A (pt) métodos para preparação de corpos de óleo compreendendo ingredientes ativos
BR9909486A (pt) Compostos calcilìticos
GT199900137A (es) Polimorfo de monohidrato de zopolrestat.
BR0208353A (pt) Compostos de diidropirimidina substituìdos com ciano e seu uso para tratar doenças
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
ES2177811T3 (es) Uso de nitroflavonoides para el tratamiento de la ansiedad.